

BB BIOVENTURES L P
Form SC 13G
May 29, 2009

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __)*
OSCIENT PHARMACEUTICALS CORP.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
68812R303
(CUSIP Number)
JANUARY 28, 2009
(Date of Event Which Requires Filing of This Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1

BB BioVentures L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Delaware

SOLE VOTING POWER

5

NUMBER OF 5,974,867*

SHARED VOTING POWER

6

SHARES BENEFICIALLY OWNED BY 0

SOLE DISPOSITIVE POWER

7

EACH REPORTING PERSON 5,974,867*

SHARED DISPOSITIVE POWER

8

WITH: 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

5,974,867*

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12.9%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

* Includes 5,973,636 shares issuable upon conversion of 12.50% Convertible Guaranteed Senior Promissory Note hold by the Reporting Person.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1

BAB BioVentures L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Delaware

SOLE VOTING POWER

5

NUMBER OF 0

SHARED VOTING POWER

6

SHARES BENEFICIALLY OWNED BY 5,974,867*

SOLE DISPOSITIVE POWER

7

EACH REPORTING PERSON 0

SHARED DISPOSITIVE POWER

8

WITH: 5,974,867*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

5,974,867*

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12.9%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

* These shares are beneficially owned directly by BB BioVentures L.P. The Reporting Person is the direct general partner of BB BioVentures L.P.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1

BAB BioVentures, N.V.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Netherlands Antilles

SOLE VOTING POWER

5

NUMBER OF 0

SHARED VOTING POWER

SHARES BENEFICIALLY OWNED BY 6

5,974,867*

SOLE DISPOSITIVE POWER

EACH REPORTING PERSON 7

0

SHARED DISPOSITIVE POWER

WITH: 8

5,974,867*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

5,974,867*

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12.9%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

* These shares are beneficially owned directly by BB BioVentures L.P. The Reporting Person is the indirect general partner of BB BioVentures L.P.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1

MPM BioVentures Parallel Fund, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Delaware

SOLE VOTING POWER

5

NUMBER OF 728,641*

SHARED VOTING POWER

6

SHARES BENEFICIALLY OWNED BY 0

SOLE DISPOSITIVE POWER

7

EACH REPORTING PERSON 728,641*

SHARED DISPOSITIVE POWER

8

WITH: 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

728,641*

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.6%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

* Includes 727,272 shares issuable upon conversion of 12.50% Convertible Guaranteed Senior Promissory Note hold by the Reporting Person.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1

MPM BioVentures I L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Delaware

SOLE VOTING POWER

5

NUMBER OF 0

SHARED VOTING POWER

6

SHARES BENEFICIALLY OWNED BY 728,641*

SOLE DISPOSITIVE POWER

7

EACH REPORTING PERSON 0

SHARED DISPOSITIVE POWER

8

WITH: 728,641*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

728,641*

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.6%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

* These shares are beneficially owned directly by MPM BioVentures Parallel Fund, LP. The Reporting Person is the direct general partner of MPM BioVentures Parallel Fund, L.P.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1

MPM BioVentures I LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Delaware

SOLE VOTING POWER

5

NUMBER OF 0

SHARED VOTING POWER

SHARES BENEFICIALLY OWNED BY 6

728,641*

SOLE DISPOSITIVE POWER

EACH REPORTING PERSON 7

0

SHARED DISPOSITIVE POWER

WITH: 8

728,641*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

728,641*

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.6%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

* These shares are beneficially owned directly by MPM BioVentures Parallel Fund, L.P. The Reporting Person is the indirect general partner of MPM BioVentures Parallel Fund, L.P.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1 MPM Asset Management Investors 1998 LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)
(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4 Delaware

SOLE VOTING POWER

5 NUMBER OF 77,985*

SHARED VOTING POWER

6 SHARES BENEFICIALLY OWNED BY 0

SOLE DISPOSITIVE POWER

7 EACH REPORTING PERSON 77,985*

SHARED DISPOSITIVE POWER

8 WITH: 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9 77,985*

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.2%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

* Includes 76,363 shares issuable upon conversion of 12.50% Convertible Guaranteed Senior Promissory Note hold by the Reporting Person.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1 Evinin, Luke

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)
(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4 United States of America

SOLE VOTING POWER

5
NUMBER OF 0

SHARED VOTING POWER

6
SHARES BENEFICIALLY OWNED BY 6,781,493*

SOLE DISPOSITIVE POWER

7
EACH REPORTING PERSON 0

SHARED DISPOSITIVE POWER

8
WITH: 6,781,493*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9 6,781,493*

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

10

o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11

14.7%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12

IN

* These shares are beneficially owned directly as follows: 5,974,867 by BB BioVentures L.P.; 728,641 by MPM BioVentures Parallel Fund, L.P.; and 77,985 by MPM Asset Management Investors 1998 LLC. BAB BioVentures L.P. and BAB BioVentures, N.V. are the direct and indirect general partners of BB BioVentures L.P. MPM BioVentures I L.P. and MPM BioVentures I LLC are the direct and indirect general partners of MPM BioVentures Parallel Fund, L.P. The Reporting person is a manager of BAB BioVentures, N.V., MPM BioVentures I LLC and MPM Asset Management Investors 1998 LLC. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1

Gadicke, Ansbert

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

United States of America

SOLE VOTING POWER

5

NUMBER OF 0

SHARED VOTING POWER

SHARES BENEFICIALLY OWNED BY 6

6,781,493*

SOLE DISPOSITIVE POWER

EACH REPORTING PERSON 7

0

SHARED DISPOSITIVE POWER

WITH: 8

6,781,493*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

6,781,493*

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

10

o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11

14.7%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12

IN

* These shares are beneficially owned directly as follows: 5,974,867 by BB BioVentures L.P.; 728,641 by MPM BioVentures Parallel Fund, L.P.; and 77,985 by MPM Asset Management Investors 1998 LLC. BAB BioVentures L.P. and BAB BioVentures, N.V. are the direct and indirect general partners of BB BioVentures L.P. MPM BioVentures I L.P. and MPM BioVentures I LLC are the direct and indirect general partners of MPM BioVentures Parallel Fund, L.P. The Reporting person is a manager of BAB BioVentures, N.V., MPM BioVentures I LLC and MPM Asset Management Investors 1998 LLC. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.

CUSIP No. 68812R303

NAME OF REPORTING PERSONS

1 Steinmetz, Michael

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)
(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4 United States of America

SOLE VOTING POWER

5
NUMBER OF 0

SHARED VOTING POWER

6
SHARES BENEFICIALLY OWNED BY 6,781,493*

SOLE DISPOSITIVE POWER

7
EACH REPORTING PERSON 0

SHARED DISPOSITIVE POWER

8
WITH: 6,781,493*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9 6,781,493*

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

10

o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11

14.7%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12

IN

* These shares are beneficially owned directly as follows: 5,974,867 by BB BioVentures L.P.; 728,641 by MPM BioVentures Parallel Fund, L.P.; and 77,985 by MPM Asset Management Investors 1998 LLC. BAB BioVentures L.P. and BAB BioVentures, N.V. are the direct and indirect general partners of BB BioVentures L.P. MPM BioVentures I L.P. and MPM BioVentures I LLC are the direct and indirect general partners of MPM BioVentures Parallel Fund, L.P. The Reporting person is a manager of BAB BioVentures, N.V., MPM BioVentures I LLC and MPM Asset Management Investors 1998 LLC. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.

Item 1.

(a) Name of Issuer

Oscient Pharmaceuticals Corp.

(b) Address of Issuer's Principal Executive Offices

1000 Winter Street, Suite 2200

Waltham, MA 02451

Item 2.

(a) Name of Person Filing

BB BioVentures L.P.

BAB BioVentures L.P.

BAB BioVentures, N.V.

MPM BioVentures Parallel Fund, L.P.

MPM BioVentures I L.P.

MPM BioVentures I LLC

MPM Asset Management Investors 1998 LLC

Evnin, Luke

Gadicke, Ansbert

Steinmetz, Michael

(b) Address of Principal Business Office or, if none, Residence

c/o MPM Asset Management

The John Hancock Tower

200 Clarendon Street, 54th Floor

Boston, Massachusetts 02116

(c) Citizenship

All entities were organized in Delaware except BAB BioVentures, N.V., which was organized in the Netherlands Antilles. The individuals are all United States citizens.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

68812R303

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

(a) Amount Beneficially Owned:

BB BioVentures L.P.	5,974,867(1)
BAB BioVentures L.P.	5,974,867(2)
BAB BioVentures, N.V.	5,974,867(3)
MPM BioVentures Parallel Fund, L.P.	728,641(4)
MPM BioVentures I L.P.	728,641(5)
MPM BioVentures I LLC	728,641(6)
MPM Asset Management Investors 1998 LLC	77,985(7)
Evnin, Luke	6,781,493(8)
Gadicke, Ansbert	6,781,493(8)
Steinmetz, Michael	6,781,493(8)
Percent of Class:	
BB BioVentures L.P.	12.9%
BAB BioVentures L.P.	12.9%
BAB BioVentures, N.V.	12.9%
MPM BioVentures Parallel Fund, L.P.	1.6%
MPM BioVentures I L.P.	1.6%
MPM BioVentures I LLC	0.2%
MPM Asset Management Investors 1998 LLC	0.2%
Evnin, Luke	14.7%
Gadicke, Ansbert	14.7%
Steinmetz, Michael	14.7%

(b) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

BB BioVentures L.P.	5,974,867(1)
BAB BioVentures L.P.	0
BAB BioVentures, N.V.	0
MPM BioVentures Parallel Fund, L.P.	728,641(4)
MPM BioVentures I L.P.	0
MPM BioVentures I LLC	0
MPM Asset Management Investors 1998 LLC	77,985(7)
Evnin, Luke	0
Gadicke, Ansbert	0
Steinmetz, Michael	0

(ii) Shared power to vote or to direct the vote

BB BioVentures L.P.	0
BAB BioVentures L.P.	5,974,867(2)
BAB BioVentures, N.V.	5,974,867(3)
MPM BioVentures Parallel Fund, L.P.	0
MPM BioVentures I L.P.	728,641(5)
MPM BioVentures I LLC	728,641(6)
MPM Asset Management Investors 1998 LLC	0
Evnin, Luke	6,781,493(8)
Gadicke, Ansbert	6,781,493(8)
Steinmetz, Michael	6,781,493(8)

(iii) Sole power to dispose or to direct the disposition of

BB BioVentures L.P.	5,974,867(1)
BAB BioVentures L.P.	0
BAB BioVentures, N.V.	0
MPM BioVentures Parallel Fund, L.P.	728,641(4)
MPM BioVentures I L.P.	0
MPM BioVentures I LLC	0
MPM Asset Management Investors 1998 LLC	77,985(7)
Evnin, Luke	0
Gadicke, Ansbert	0
Steinmetz, Michael	0

(iv) Shared power to dispose or to direct the disposition of

BB BioVentures L.P.	0
BAB BioVentures L.P.	5,974,867(2)
BAB BioVentures, N.V.	5,974,867(3)
MPM BioVentures Parallel Fund, L.P.	0
MPM BioVentures I L.P.	728,641(5)
MPM BioVentures I LLC	728,641(6)
MPM Asset Management Investors 1998 LLC	0
Evnin, Luke	6,781,493(8)
Gadicke, Ansbert	6,781,493(8)
Steinmetz, Michael	6,781,493(8)

(1) Includes
 5,973,636
 shares issuable
 upon conversion
 of 12.50%
 Convertible
 Guaranteed
 Senior
 Promissory
 Note hold by
 BB BioVentures
 L.P.

(2) These shares are
 beneficially
 owned directly
 by BB
 BioVentures
 L.P. BAB
 BioVentures
 L.P. is the direct
 general partner
 of BB
 BioVentures

L.P.

- (3) These shares are beneficially owned directly by BB BioVentures L.P. BAB BioVentures, N.V. is the indirect general partner of BB BioVentures L.P.
- (4) Includes 727,272 shares issuable upon conversion of 12.50% Convertible Guaranteed Senior Promissory Note hold by MPM BioVentures Parallel Fund, L.P.
- (5) These shares are beneficially owned directly by MPM BioVentures Parallel Fund, L.P. MPM BioVentures I L.P. is the direct general partner of MPM BioVentures Parallel Fund, L.P.
- (6) These shares are beneficially owned directly by MPM BioVentures Parallel Fund,

L.P. MPM
BioVentures I
LLC is the
indirect general
partner of MPM
BioVentures
Parallel Fund,
L.P.

(7) Includes 76,363
shares issuable
upon conversion
of 12.50%
Convertible
Guaranteed
Senior
Promissory
Note hold by
MPM Asset
Management
Investors 1998
LLC.

(8) These shares are
beneficially
owned directly
as follows:
5,974,867 by
BB BioVentures
L.P.; 728,641 by
MPM
BioVentures
Parallel Fund.
L.P.; and 77,985
by MPM Asset
Management
Investors 1998
LLC. BAB
BioVentures
L.P. and BAB
BioVentures,
N.V. are the
direct and
indirect general
partners of BB
BioVentures
L.P. MPM
BioVentures I
L.P. and MPM
BioVentures I
LLC are the

direct and
indirect general
partners of
MPM
BioVentures
Parallel Fund,
L.P.
Messrs. Evin,
Gadicke and
Steinmetz are
managers of
BAB
BioVentures,
N.V., MPM
BioVentures I
LLC and MPM
Asset
Management
Investors 1998
LLC. Each of
these reporting
persons
disclaims
beneficial
ownership of all
such shares
except to the
extent of his
proportionate
pecuniary
interests therein.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Page 15 of 21

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of a Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 16 of 21

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 29, 2009

BB BioVentures L.P.

By: BAB BioVentures, L.P.,
its General Partner

By: BAB BioVentures N.V.,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

BAB BioVentures, N.V.

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

MPM BioVentures I L.P.

By: MPM BioVentures I LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

BAB BioVentures L.P.

By: BAB BioVentures, N.V.,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

MPM BioVentures Parallel Fund L.P.

By: MPM BioVentures I L.P.,
its General Partner

By: MPM BioVentures I LLC,
its General Partner

By: /s/ Luke Evnin
Name: Luke Evnin
Title: Manager

MPM BioVentures I LLC

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

MPM Asset Management Investors 1998 LLC

By: /s/ Luke Evin
Name: Luke Evin
Title: Manager

/s/ Luke Evin
Luke Evin

/s/ Ansbert Gadicke
Ansbert Gadicke

/s/ Michael Steinmetz
Michael Steinmetz

EXHIBITS

A: Joint Filing Agreement

Page 19 of 21

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Oscient Pharmaceuticals Corp., Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 29th day of May, 2009.

BB BioVentures L.P.

By: BAB BioVentures, L.P.,
its General Partner

By: BAB BioVentures N.V.,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

BAB BioVentures L.P.

By: BAB BioVentures, N.V.,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

BAB BioVentures, N.V.

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

MPM BioVentures Parallel Fund L.P.

By: MPM BioVentures I L.P.,
its General Partner

By: MPM BioVentures I LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

MPM BioVentures I L.P.

By: MPM BioVentures I LLC,
its General Partner

MPM BioVentures I LLC

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Manager

Page 20 of 21

MPM Asset Management Investors 1998 LLC

By: /s/ Luke Evnin
Name: Luke Evnin
Title: Manager

/s/ Luke Evnin
Luke Evnin

/s/ Ansbert Gadicke
Ansbert Gadicke

/s/ Michael Steinmetz
Michael Steinmetz